Trial
NCT02236572
Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
Novartis Pharmaceuticals
Condition
Breast Cancer
Intervention
Everolimus
Why stopped
Phase 2 of recruitment was contingent on 5 of 15 patients responding, which did not occur.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-02-01